Outlook Therapeutics Inc — Bilancio Trimestrale (NASDAQ:OTLK) | MetaTrader

Apri il grafico completo

Notizie

Outlook Therapeutics completa riunione di risoluzione controversie FDA

Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug - Outlook Therapeu

Outlook Therapeutics presenta richiesta di risoluzione controversia con FDA

Outlook Therapeutics chiude un’offerta azionaria da 5 milioni di dollari

Outlook Therapeutics lancia offerta pubblica di azioni

Outlook Therapeutics secures $18.4M note, extends debt maturity

Outlook Therapeutics discute incontro con FDA su farmaco bevacizumab

Outlook Therapeutics discusses FDA meeting on bevacizumab drug

Oncobiologics, Inc. (OTLK) Reports Q1 Loss, Misses Revenue Estimates

OTLK Stock Crashes 67% in a Week: Here's What You Need to Know

Outlook Therapeutics: target di prezzo ridotto a $0,50 da H.C. Wainwright

Outlook Therapeutics stock price target lowered to $0.50 at H.C. Wainwright